Price
$7.97-5.79%Social Signal Score
Analyst Ratings
11 analystsRevenue
$27.71M+31.12%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jason Kelly
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 485
- Beta
- 1.75
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -9.27
Financials
Revenue
$27.71M+31.1%Net Income
$-40.98MEBITDA
$-41.26MFree Cash Flow
$-30.35MEPS (diluted)
$-0.64Shares Outstanding (diluted)
63.97M+110.1%Operating Expenses
$69.54MCash & Debt
$285.36MReturn of Capital
$0.00Revenue by Segment (annual)
$37.41MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $170.16M | $-312.76M | $-5.64 |
| 2024 | $227.04M | $-547.03M | $-10.54 |
| 2023 | $251.46M | $-892.87M | $-18.37 |
| 2022 | $477.71M | $-2.10B | $-50.15 |
| 2021 | $313.84M | $-1.83B | $-53.83 |
| 2020 | $76.66M | $-126.61M | $-3.97 |
| 2019 | $54.18M | $-119.33M | $-4.15 |
Valuation
DNAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
10-80.00%Social Signal Score
Mentions (19)
- Newsglobenewswire.com·12d ago·Negative
Rakovina Therapeutics Secures Exclusive Worldwide Licence to Artemis.AI™ Platform for DNA-Damage Response Oncology Drug Discovery Perpetual, royalty-free, exclusive licence for DDR oncology including all future platform improvements, in exchange for C$1.0 million in Rakovina shares Perpetual, royalty-free, exclusive licence for DDR oncology including all future platform improvements, in exchange for C$1.0 million in Rakovina shares
View source ↗ - Newsfool.com·15d ago·Positive
Ginkgo Bioworks: 3 Key Takeaways for Long-Term Investors Novo Nordisk selected Ginkgo to build an autonomous research laboratory. Ginkgo ended the third quarter with $285 million in cash.
View source ↗ - Newsmarketbeat.com·15d ago·Negative
Ginkgo Bioworks Q3 Earnings Call Highlights Ginkgo Bioworks NYSE: DNA reported lower third-quarter revenue but narrowed its loss as restructuring-related expense cuts took hold, while executives highlighted new customers for its autonomous laboratory systems and cloud-based lab services.
View source ↗ - Newsseekingalpha.com·16d ago·Positive
Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2026 Earnings Call Transcript Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·24d ago·Neutral
Ginkgo Bioworks Holdings, Inc. (DNA) Suffers a Larger Drop Than the General Market: Key Insights Ginkgo Bioworks Holdings, Inc. (DNA) closed at $12.74 in the latest trading session, marking a -4.35% move from the prior day.
View source ↗ - Newsbusinessinsider.com·31d ago·Neutral
Hugging Face is launching a new AI model that lets scientists 'chat with DNA' Hugging Face released a new AI model that allows users to "chat with DNA." Carbon-X can analyze and generate DNA and allows researchers to ask questions in plain language.
View source ↗ - Newsglobenewswire.com·32d ago·Negative
Cerenome Announces New Dual Mechanism of Action Featuring Lethal DNA Damage and Beneficial Immunomodulation Supporting Lead Investigational Drug REYOBIQ™ Findings suggest a dual mechanism of action for REYOBIQ against cancer cells New findings revealed potential dual mechanism as combinations with checkpoint blockade further enhanced REYOBIQ therapeutic action in multiple cancers HOUSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company") today announce…
View source ↗ - Newszacks.com·33d ago·Negative
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to Know Ginkgo Bioworks Holdings, Inc. (DNA) reached $9.86 at the closing of the latest trading day, reflecting a -2.09% change compared to its last close.
View source ↗ - Newszacks.com·39d ago·Neutral
Here's Why Ginkgo Bioworks Holdings, Inc. (DNA) Fell More Than Broader Market In the most recent trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $11.53, indicating a -1.96% shift from the previous trading day.
View source ↗ - Newsbusinesswire.com·45d ago·Positive
…bs Researchers, Contributing Cloud Lab Time and Protein Testing Services to $1.5 Billion Breakthrough Science Program BOSTON--(BUSINESS WIRE)--Ginkgo Bioworks (NYSE: DNA) today announced that it will provide in-kind access to its autonomous laboratory in Boston to support the National Science Foundation's X-Labs program. Ginkgo's support was announced today by Michael Kratsios, Director of the White House Office of Science and Technology Policy (OSTP), at the Science: A New Golden Age Summit in …
View source ↗ - Newsprnewswire.com·45d ago·Neutral
Araceli Biosciences and Ginkgo Bioworks Bring Cellular Imaging at Scale to Nebula's Lab-in-the-Loop The Endeavor® adds the fastest high-content cellular data generation to Ginkgo's around-the-clock research PORTLAND, Ore. and BOSTON, Oct. 8, 2026 /PRNewswire/ -- Araceli Biosciences and Ginkgo Bioworks (NYSE: DNA) today announced the integration of Araceli's Endeavor® high-content imaging instrument into Nebula, Ginkgo's autonomous lab in Boston.
View source ↗ - Newszacks.com·46d ago·Neutral
Ginkgo Bioworks Holdings, Inc. (DNA) Falls More Steeply Than Broader Market: What Investors Need to Know Ginkgo Bioworks Holdings, Inc. (DNA) closed the most recent trading day at $11.47, moving 7.57% from the previous trading session.
View source ↗ - Newszacks.com·52d ago·Negative
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to Know In the closing of the recent trading day, Ginkgo Bioworks Holdings, Inc. (DNA) stood at $12.5, denoting a -2.57% move from the preceding trading day.
View source ↗ - Newsglobenewswire.com·59d ago·Negative
Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products Agreement would expand the companies' genetic testing collaboration beyond ophthalmology to a selected suite of genomic testing products through an additional U.S. reseller channel Agreement would expand the companies' genetic testing collaboration beyond ophthalmology to a selected suite of genomic testing products through an additional U.S. reseller channel
View source ↗ - Newszacks.com·60d ago·Neutral
Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $8.58, marking a -8.43% move from the previous day.
View source ↗ - Newszacks.com·65d ago·Positive
Ginkgo Bioworks (DNA) Surges 11.1%: Is This an Indication of Further Gains? Ginkgo Bioworks (DNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
View source ↗ - Newszacks.com·67d ago·Neutral
Ginkgo Bioworks Holdings, Inc. (DNA) Rises As Market Takes a Dip: Key Facts Ginkgo Bioworks Holdings, Inc. (DNA) concluded the recent trading session at $7.06, signifying a +1% move from its prior day's close.
View source ↗ - Newsglobenewswire.com·95d ago·Negative
DNA X, Inc. Reports Second Quarter 2026 Financial Results - Strengthened balance sheet with $1.8 million cash from new convertible debt in Q2 and additional $5.0 million through the sale of preferred stock after quarter end
View source ↗ - Newsmarketbeat.com·106d ago·Neutral
Ginkgo Bioworks Q2 Earnings Call Highlights Ginkgo Bioworks NYSE: DNA reported second-quarter 2026 revenue of $20 million, down 48% from the year-earlier period, as the company continued to shift its focus toward autonomous laboratory systems, contract research services and related software.
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $-1.04 per share
Typical surprise +5.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$-0.64 vs $-0.68beat
- Wed, Aug 5$-0.75 vs $-0.90beat
- Thu, May 7$-1.39 vs $-1.21miss
- Thu, Feb 26$-1.42 vs $-1.80beat
- Thu, Nov 6$-1.45 vs $-1.24miss
- Thu, Aug 7$-1.10 vs $-1.44beat
Estimates and results for DNA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DNA officers and directors.
- Bought
- —
- Sold
- $4.9m
0 trades
22 trades
- Coen Steven P.sold
- Canton Barrysold
- Canton Barrysold
- Shetty Reshma P.sold
- Shetty Reshma P.sold
- Kelly Jason Rsold
- Coen Steven P.sold
- Henry Christian Osold
78 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in DNA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
